Chapel H - Search Results

1

Šedivá A, Chapel H, Gardulf A; European Immunoglobulin Map Group (35 European Countries) for European Society for Immunodeficiencies (ESID) Primary Immunodeficiencies Care in Development Working Party. Šedivá A, et al. Among authors: chapel h. Clin Exp Immunol. 2014 Dec;178 Suppl 1(Suppl 1):141-3. doi: 10.1111/cei.12546. Clin Exp Immunol. 2014. PMID: 25546797 Free PMC article. No abstract available.

2

Subcutaneous immunoglobulin replacement therapy: the European experience.

Chapel H, Gardulf A. Chapel H, et al. Curr Opin Allergy Clin Immunol. 2013 Dec;13(6):623-9. doi: 10.1097/ACI.0000000000000013. Curr Opin Allergy Clin Immunol. 2013. PMID: 24126615 Review.

3

When to initiate immunoglobulin replacement therapy (IGRT) in antibody deficiency: a practical approach.

Jolles S, Chapel H, Litzman J. Jolles S, et al. Among authors: chapel h. Clin Exp Immunol. 2017 Jun;188(3):333-341. doi: 10.1111/cei.12915. Epub 2017 Jan 30. Clin Exp Immunol. 2017. PMID: 28000208 Free PMC article. Review.

4

Prospective audit of adverse reactions occurring in 459 primary antibody-deficient patients receiving intravenous immunoglobulin.

Brennan VM, Salomé-Bentley NJ, Chapel HM; Immunology Nurses Study. Brennan VM, et al. Among authors: chapel hm. Clin Exp Immunol. 2003 Aug;133(2):247-51. doi: 10.1046/j.1365-2249.2003.02199.x. Clin Exp Immunol. 2003. PMID: 12869031 Free PMC article.

5

Immunoglobulin replacement therapy by self-infusion at home.

Chapel H, Brennan V, Delson E. Chapel H, et al. Clin Exp Immunol. 1988 Jul;73(1):160-2. Clin Exp Immunol. 1988. PMID: 3168330 Free PMC article.

6

The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy.

Chapel HM, Spickett GP, Ericson D, Engl W, Eibl MM, Bjorkander J. Chapel HM, et al. J Clin Immunol. 2000 Mar;20(2):94-100. doi: 10.1023/a:1006678312925. J Clin Immunol. 2000. PMID: 10821460 Clinical Trial.

7

Therapeutic immunoglobulin should be dosed by clinical outcome rather than by body weight in obese patients.

Hodkinson JP, Lucas M, Lee M, Harrison M, Lunn MP, Chapel H. Hodkinson JP, et al. Among authors: chapel h. Clin Exp Immunol. 2015 Jul;181(1):179-87. doi: 10.1111/cei.12616. Epub 2015 May 25. Clin Exp Immunol. 2015. PMID: 25731216 Free PMC article.

8

Immunoglobulin replacement in patients with chronic lymphocytic leukemia (CLL): kinetics of immunoglobulin metabolism.

Chapel HM, Lee M. Chapel HM, et al. J Clin Immunol. 1992 Jan;12(1):17-20. doi: 10.1007/BF00918268. J Clin Immunol. 1992. PMID: 1551938 Clinical Trial.

9

Assessment of Local Adverse Reactions to Subcutaneous Immunoglobulin (SCIG) in Clinical Trials.

Ballow M, Wasserman RL, Jolles S, Chapel H, Berger M, Misbah SA. Ballow M, et al. Among authors: chapel h. J Clin Immunol. 2017 Aug;37(6):517-518. doi: 10.1007/s10875-017-0410-x. Epub 2017 Jul 10. J Clin Immunol. 2017. PMID: 28695366 Free PMC article. No abstract available.

10

Recognition, clinical diagnosis and management of patients with primary antibody deficiencies: a systematic review.

Wood P, Stanworth S, Burton J, Jones A, Peckham DG, Green T, Hyde C, Chapel H; UK Primary Immunodeficiency Network. Wood P, et al. Among authors: chapel h. Clin Exp Immunol. 2007 Sep;149(3):410-23. doi: 10.1111/j.1365-2249.2007.03432.x. Epub 2007 Jun 12. Clin Exp Immunol. 2007. PMID: 17565605 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

224 results

Search Page

Filters